Ignite Creation Date:
2025-12-24 @ 7:24 PM
Ignite Modification Date:
2025-12-25 @ 5:04 PM
Study NCT ID:
NCT05005403
Status:
RECRUITING
Last Update Posted:
2025-10-28
First Post:
2021-08-12
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of Azirkitug (ABBV-514) Alone or in Combination With Budigalimab or Bevacizumab
Sponsor:
AbbVie
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-11-01
Start Date Type:
ACTUAL
Primary Completion Date:
2026-07
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-06
Completion Date Type:
ESTIMATED
First Submit Date:
2021-08-12
First Submit QC Date:
None
Study First Post Date:
2021-08-13
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-10-27
Last Update Post Date:
2025-10-28
Last Update Post Date Type:
ESTIMATED